Seroatlas · Human Serome Atlas

TOM1

Target of Myb1 membrane trafficking protein

Also known as: TOM1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: O60784
Gene: TOM1
Ensembl: ENSG00000100284
Chromosome: 22
Canonical length: 492 aa
Protein class: Cancer-related genes, Disease related genes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters
Subcellular location: Golgi apparatus,Cytosol

OverviewNCBI Gene

This gene was identified as a target of the v-myb oncogene. The encoded protein shares its N-terminal domain in common with proteins associated with vesicular trafficking at the endosome. It is recruited to the endosomes by its interaction with endofin. Several alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2008]

Canonical amino-acid sequenceUniProt

492 residues, UniProt reviewed canonical sequence.

>O60784|TOM1
     1  MDFLLGNPFS SPVGQRIEKA TDGSLQSEDW ALNMEICDII NETEEGPKDA LRAVKKRIVG
    61  NKNFHEVMLA LTVLETCVKN CGHRFHVLVA SQDFVESVLV RTILPKNNPP TIVHDKVLNL
   121  IQSWADAFRS SPDLTGVVTI YEDLRRKGLE FPMTDLDMLS PIHTPQRTVF NSETQSGQDS
   181  VGTDSSQQED SGQHAAPLPA PPILSGDTPI APTPEQIGKL RSELEMVSGN VRVMSEMLTE
   241  LVPTQAEPAD LELLQELNRT CRAMQQRVLE LIPQIANEQL TEELLIVNDN LNNVFLRHER
   301  FERFRTGQTT KAPSEAEPAA DLIDMGPDPA ATGNLSSQLA GMNLGSSSVR AGLQSLEASG
   361  RLEDEFDMFA LTRGSSLADQ RKEVKYEAPQ ATDGLAGALD ARQQSTGAIP VTQACLMEDI
   421  EQWLSTDVGN DAEEPKGVTS EEFDKFLEER AKAADRLPNL SSPSAEGPPG PPSGPAPRKK
   481  TQEKDDDMLF AL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TOM1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Other membrane
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.46
Highest tissue expression: 213 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 213 nTPM
esophagus: 79 nTPM
skin: 75 nTPM
tongue: 64 nTPM
bone marrow: 57 nTPM
salivary gland: 57 nTPM

Single-cell type

neutrophils: 1,089 nCPM
esophageal apical cells: 627 nCPM
syncytiotrophoblasts: 382 nCPM
monocytes: 302 nCPM
endometrial glandular cells: 274 nCPM
esophageal suprabasal cells: 166 nCPM

Immune cell

neutrophil: 130 nTPM
classical monocyte: 101 nTPM
non-classical monocyte: 67 nTPM
total PBMC: 63 nTPM
intermediate monocyte: 61 nTPM
T-reg: 48 nTPM

Brain region

pons: 59 nTPM
hypothalamus: 46 nTPM
thalamus: 43 nTPM
midbrain: 42 nTPM
medulla oblongata: 42 nTPM
cerebral cortex: 42 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about TOM1.

Disease | AllUniProt

Conditions TOM1 is implicated in, by any mechanism.

Immunodeficiency 85 (IMD85) MIM:619510

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 134 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Immunodeficiency 85 and autoimmunity

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.04
gnomAD pLI: 0
gnomAD missense Z: 1.08
DepMap mean gene effect: -0.1
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TOM1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TOM1 as an antibody target. Whether an autoantibody or antibody against TOM1 could matter depends on whether native TOM1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TOM1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label TOM1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...